Searching over 5,500,000 cases.

Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

Hall v. Bayer Corp.

United States District Court, E.D. Missouri, Eastern Division

January 10, 2017

JAMIE HALL, et al., Plaintiffs,
BAYER CORP. et al., Defendants.



         This matter is before the Court on plaintiffs' motion to remand the action to the state court from which it was removed. Defendants have filed a response in opposition, a motion to dismiss the claims of all non-Missouri plaintiffs for lack of personal jurisdiction, and a motion to sever the plaintiffs' claims. Both sides have filed notices of supplemental authority, which the Court has reviewed. All issues are fully briefed.

         I. Background

         On July 28, 2016, 94 individuals filed suit in the Twenty-Second Judicial Circuit (St. Louis City) seeking damages for injuries arising from use of Essure, an implanted birth control device manufactured by defendants. Plaintiffs are citizens of several states, including Missouri, Indiana, Pennsylvania, and New Jersey. Defendant Bayer Corporation is a citizen of Indiana, where it is incorporated, and Pennsylvania, where it has its principal place of business; defendant Bayer HealthCare LLC, is a limited liability company formed under the laws of Delaware whose nine members are citizens of Delaware, New Jersey, Pennsylvania, the Netherlands, and Germany; defendants Bayer Essure Inc., and Bayer HealthCare Pharmaceuticals Inc., are citizens of Delaware and New Jersey; and Bayer AG is a citizen of Germany. [see Notice of Removal, Doc. # 1 at ¶¶ 23-27]. Defendants removed the case to this Court invoking jurisdiction based on diversity of citizenship, pursuant to 28 U.S.C. § 1332(a)(1), federal question jurisdiction, pursuant to 28 U.S.C. § 1331, and mass action jurisdiction pursuant to the Class Action Fairness Act (CAFA), 28 U.S.C. § 1332(d).

         II. Legal Standard

         “A defendant may remove a state law claim to federal court only if the action originally could have been filed there.” In re Prempro Products Liability Litigation, 591 F.3d 613, 619 (8th Cir. 2010) (citing Phipps v. FDIC, 417 F.3d 1006, 1010 (8th Cir. 2005)). The removing defendant bears the burden of establishing federal jurisdiction by a preponderance of the evidence. Altimore v. Mount Mercy College, 420 F.3d 763, 768 (8th Cir. 2005). “All doubts about federal jurisdiction should be resolved in favor of remand to state court.” In re Prempro, 591 F.3d at 620 (citing Wilkinson v. Shackelford, 478 F.3d 957, 963 (8th Cir. 2007)). A case must be remanded if, at anytime, it appears that the district court lacks subject-matter jurisdiction. 28 U.S.C. § 1447(c); Fed.R.Civ.P. 12(h)(3).

         III. Discussion

         “It is axiomatic that a court may not proceed at all in a case unless it has jurisdiction.” Crawford v. F. Hoffman-La Roche Ltd., 267 F.3d 760, 764 (8th Cir. 2001). Defendants argue that, in this case, the Court should dismiss the claims of the non-Missouri plaintiffs for lack of personal jurisdiction before addressing subject matter jurisdiction.[1]

         Under Ruhrgas AG v. Marathon Oil Co., 526 U.S. 574 (1999), the Court has discretion to determine whether to consider its subject-matter jurisdiction or personal jurisdiction first. Where, as here, the inquiry into subject matter jurisdiction is not arduous, the better course is to address that issue first. See id. at 587-88 (“[B]oth expedition and sensitivity to state courts' coequal stature should impel the federal court to dispose of [subject matter jurisdiction] first.”) Courts in this district addressing cases removed on the basis of similar personal-jurisdiction arguments have found it appropriate to address the issue of subject matter jurisdiction first. See, e.g., Mounce v. Bayer Corp., No. 4:16-CV-1478 (RLW), 2016 WL 7235707 (E.D. Mo. Dec. 13, 2016); Dorman v. Bayer Corp., No. 4:16-CV-601 (HEA), 2016 WL 7033765 (E.D. Mo. Dec. 2, 2016); Fahnestock v. Boehringer Ingelheim Pharm., Inc., No. 4:16-CV-1013 (CEJ), 2016 WL 4397971, at *1 (E.D. Mo. Aug. 18, 2016); Timms v. Johnson & Johnson, No. 4:16-CV-733 (JAR), 2016 WL 3667982 (E.D. Mo. July 11, 2016); Joseph v. Combe Inc., No. 4:16-CV-284 (RLW), 2016 WL 3339387 (E.D. Mo. June 13, 2016); Nickerson v. Janssen Pharm., Inc., No. 4:15-CV-1762 (RLW), 2016 WL 3030241 (E.D. Mo. May 26, 2016); Adler v. Boehringer Ingelheim Pharm., Inc., No. 4:16-CV-155 (RWS), Memorandum and Order (E.D. Mo. Mar. 28, 2016) [Doc. #18]; Clark v. Pfizer, No. 4:15-CV-456 (HEA), 2015 WL 4648019 (E.D. Mo. Aug. 5, 2015); Parker v. Pfizer, Inc., No. 4:15-CV-441 (CAS), 2015 WL 3971169 (E.D. Mo. June 30, 2015); Littlejohn v. Janssen Research & Dev., LLC, No. 4:15-CV-194 (NAB/CDP), 2015 WL 1647901 (E.D. Mo. Apr. 13, 2015). The Court agrees that it is appropriate to determine whether it has subject matter jurisdiction before addressing the issue of personal jurisdiction.

         A. Diversity Jurisdiction

         Diversity jurisdiction under 28 U.S.C. § 1332 requires an amount in controversy greater than $75, 000, exclusive of interest and costs, and complete diversity of citizenship among the litigants. “Complete diversity of citizenship exists where no defendant holds citizenship in the same state where any plaintiff holds citizenship.” OnePoint Solutions, LLC v. Borchert, 486 F.3d 342, 346 (8th Cir. 2007).

         The doctrine of fraudulent joinder is an exception to the complete diversity rule. In re Prempro, 591 F.3d at 620. “The doctrine of fraudulent joinder allows a district court to assume jurisdiction over a facially nondiverse case temporarily and, if there is no reasonable basis for the imposition of liability under state law, dismiss the nondiverse party from the case and retain subject matter jurisdiction over the remaining claims.” Murphy v. Aurora Loan Servs., LLC, 699 F.3d 1027, 1031 (8th Cir. 2012), as corrected (Nov. 28, 2012). Defendants argue that the nondiverse plaintiffs are fraudulently joined because the Court does not have personal jurisdiction over defendants for the claims brought by the non-Missouri plaintiffs.

         “Fraudulent joinder occurs when a plaintiff files a frivolous or illegitimate claim against a non-diverse defendant solely to prevent removal.” In re Prempro, 591 F.3d at 620. To prove fraudulent joinder, the removing party must show that “the plaintiff's claim against the diversity-destroying defendant has ‘no reasonable basis in fact and law.'” Knudson v. Sys. Painters, Inc., 634 F.3d 968, 980 (8th Cir. 2011) (quoting Filla v. Norfolk S. Ry. Co., 336 F.3d 806, 810 (8th Cir. 2003)). “[I]f it is clear under governing state law that the complaint does not state a cause of action against the non-diverse defendant, the joinder is fraudulent.” Id. (emphasis in original). Conversely, “joinder is not fraudulent where ‘there is arguably a reasonable basis for predicting that the state law might impose liability based upon the facts involved.'” Id. (quoting Filla, 336 F.3d at 811).

         Courts in this district have repeatedly held that an alleged lack of personal jurisdiction does not establish fraudulent joinder. See Mounce, 2016 WL 7235707, at *3; Adler, No. 4:16-CV-155 at 4; Joseph v. Combe Inc., 2016 WL 3339387, at *2; Triplett v. Janssen Pharms., Inc., No. 4:14-CV-2049 (AGF), at 9 (E.D. Mo. July 7, 2015) [Doc. #30] (finding defendants' personal jurisdiction argument failed to address whether nondiverse plaintiffs had colorable claims as required to show fraudulent joinder); Gracey v. Janssen Pharms., Inc., No. 4:15-CV-407 (CEJ), 2015 WL 2066242, at *3 (E.D. Mo. May 4, 2015) (rejecting defendants' attempt to premise a fraudulent joinder argument on the state court's alleged lack of personal jurisdiction); Littlejohn, 2015 WL 1647901, at *1; Simmons v. Skechers USA, Inc., No. 4:15-CV-340 (CEJ), 2015 WL 1604859, at *3 (E.D. Mo. Apr. 9, 2015) (rejecting defendants' argument that the “theory of fraudulent joinder-an inquiry into substantive viability of claims-countenances a procedural challenge to a court's personal jurisdiction over a defendant.”) Furthermore, this Court has determined “[o]n numerous occasions . . . that the joinder of plaintiffs alleging injury from a single drug is not ‘egregious, ' because common issues of law and fact connect the plaintiffs' claims." Robinson v. Pfizer ...

Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.